Structural characterization of the SARS-coronavirus spike S fusion protein core.
about
Discovery of small-molecule HIV-1 fusion and integrase inhibitors oleuropein and hydroxytyrosol: Part I. fusion [corrected] inhibitionMolecular mechanisms of severe acute respiratory syndrome (SARS)Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitorSevere acute respiratory syndrome coronavirus as an agent of emerging and reemerging infectionA general strategy to endow natural fusion-protein-derived peptides with potent antiviral activityA recombinant avian infectious bronchitis virus expressing a heterologous spike gene belonging to the 4/91 serotypeSARS molecular epidemiology: a Chinese fairy tale of controlling an emerging zoonotic disease in the genomics era.Identification of the membrane-active regions of the severe acute respiratory syndrome coronavirus spike membrane glycoprotein using a 16/18-mer peptide scan: implications for the viral fusion mechanismIdentification of a new region of SARS-CoV S protein critical for viral entryIdentification of N-linked carbohydrates from severe acute respiratory syndrome (SARS) spike glycoprotein.Identification of a novel coronavirus in bats.Identification and characterization of the putative fusion peptide of the severe acute respiratory syndrome-associated coronavirus spike proteinInhibiting HIV fusion with a beta-peptide foldamer.Contributions of the viral genetic background and a single amino acid substitution in an immunodominant CD8+ T-cell epitope to murine coronavirus neurovirulence.Substitution at aspartic acid 1128 in the SARS coronavirus spike glycoprotein mediates escape from a S2 domain-targeting neutralizing monoclonal antibodyThe spike protein of SARS-CoV--a target for vaccine and therapeutic development.Monoclonal antibodies targeting the HR2 domain and the region immediately upstream of the HR2 of the S protein neutralize in vitro infection of severe acute respiratory syndrome coronavirus.Antiviral drugs specific for coronaviruses in preclinical developmentHuman monoclonal antibodies against highly conserved HR1 and HR2 domains of the SARS-CoV spike protein are more broadly neutralizingThe cholera toxin A1(3) subdomain is essential for interaction with ADP-ribosylation factor 6 and full toxic activity but is not required for translocation from the endoplasmic reticulum to the cytosolStructural characterization of the fusion-active complex of severe acute respiratory syndrome (SARS) coronavirus.In vitro selection and characterization of HIV-1 variants with increased resistance to sifuvirtide, a novel HIV-1 fusion inhibitor.Functional characterization of heptad repeat 1 and 2 mutants of the spike protein of severe acute respiratory syndrome coronavirus.Novel inhibitors of severe acute respiratory syndrome coronavirus entry that act by three distinct mechanismsSupramolecular architecture of severe acute respiratory syndrome coronavirus revealed by electron cryomicroscopy.The cytoplasmic tail of the severe acute respiratory syndrome coronavirus spike protein contains a novel endoplasmic reticulum retrieval signal that binds COPI and promotes interaction with membrane protein.Ready, set, fuse! The coronavirus spike protein and acquisition of fusion competenceSARS vaccine developmentSpecific asparagine-linked glycosylation sites are critical for DC-SIGN- and L-SIGN-mediated severe acute respiratory syndrome coronavirus entry.A single native ganglioside GM1-binding site is sufficient for cholera toxin to bind to cells and complete the intoxication pathway.Potential antivirals and antiviral strategies against SARS coronavirus infections.Development of Small-molecule HIV Entry Inhibitors Specifically Targeting gp120 or gp41Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein.The chromosomal nature of LT-II enterotoxins solved: a lambdoid prophage encodes both LT-II and one of two novel pertussis-toxin-like toxin family members in type II enterotoxigenic Escherichia coli.Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity.Peptide nanoparticles as novel immunogens: design and analysis of a prototypic severe acute respiratory syndrome vaccine.Role of spike protein endodomains in regulating coronavirus entry.Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential.Cholesterol-conjugated peptide antivirals: a path to a rapid response to emerging viral diseases.Identification of two neutralizing regions on the severe acute respiratory syndrome coronavirus spike glycoprotein produced from the mammalian expression system.
P2860
Q24644512-DE3328A4-A195-4B58-B228-431EA731F086Q24799739-702BC5FC-7BD7-4360-A13B-1DCA208CF4C1Q27689029-7717E9C8-0CC3-45E2-915B-DB95F46456F4Q28383088-3ABCFE99-0723-41E5-AE07-B08D1FB39EF7Q28729918-43FCEAC4-3F64-4B8B-A799-5B91901CD974Q28740826-66DBC788-13B7-4938-861A-572BE9687430Q30360085-DABFF3DB-441E-454D-B575-D41363F8367CQ30775494-7D64A50F-0CE2-4628-905B-C2DBF0F7A284Q33512190-0F275CEC-5F25-45E6-9A6A-3F21CB551539Q33529338-2CFECC63-A6DC-44FF-A6DE-44E150E6C1CDQ33782401-132E8BCA-3031-45A9-88CD-D69F52EA8F0DQ33788831-5DF64FD6-87A6-4B88-B917-A7398F5A40EAQ33862300-B9FF3C97-43B2-464C-A014-4D7D1D626699Q33883823-400D030F-7D4D-4DC8-A9A2-7A06627B4EE6Q33897964-CE250144-096C-4FCF-9EE2-1491A6CD7E87Q34015988-E6186824-6A1D-42D9-BD40-326ACA8D332BQ34301708-56900E09-7331-4BB4-BD55-5F1D94EEEF3FQ34332580-9B396E10-E41B-4F64-ABB8-3E85F8FFAFA7Q34491357-B4DA3022-E88A-44B2-B87E-FAD0CA7D1788Q34492828-441EDED2-860F-46C9-B46E-17245AFC49ECQ34514760-4FE50BF8-0C47-49ED-B645-4BC34983D47EQ34536817-BB49B937-C727-4A66-9FA7-D5F9AC500EF4Q34545772-FBA5D179-E6EC-4DBE-BA71-FD127A623059Q34725136-E3AF3683-9D27-49A0-BA83-842A8C0AE6DAQ35024038-AF7BBFC3-7D81-48A1-9882-EC2DBC95BF9FQ35784645-BC6CEC78-E70F-468D-91C8-6650D205C1E6Q35943657-C6A431B1-2607-4792-A651-0D087A706601Q36021976-BEEEB632-30B8-4D93-8F6B-46FAC1ABC905Q36315018-89A1029B-815F-4E6E-BA2F-923F0FFD57D2Q36367517-0B1FA496-C42E-4318-B315-C4AE8089F811Q36441511-35D53E22-7798-44A6-881B-0B80F5B6560FQ36643050-F768E15F-C827-434E-A0AC-26BE6789D7CDQ36972346-C3BCA04F-640D-416C-9797-AB0086CC5C7CQ37119104-EC81ED5C-B315-4686-B13D-F18F63B8ACE6Q37366744-F198F348-E0AE-43D1-95D4-3A1194918C42Q37373733-443B573D-1387-45FC-A43A-EC873692F074Q37432095-C2C0690A-B8E3-4D5F-8412-07FF28E03BA8Q37929687-FCDF91F3-886E-4A3E-847E-1AC0BC5BA67BQ38261556-F88FE00A-AA21-4899-97A5-BB8A0559471CQ40471278-7F5E1579-9E0B-4267-B7EE-1FD23B0854D0
P2860
Structural characterization of the SARS-coronavirus spike S fusion protein core.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Structural characterization of the SARS-coronavirus spike S fusion protein core.
@en
Structural characterization of the SARS-coronavirus spike S fusion protein core.
@nl
type
label
Structural characterization of the SARS-coronavirus spike S fusion protein core.
@en
Structural characterization of the SARS-coronavirus spike S fusion protein core.
@nl
prefLabel
Structural characterization of the SARS-coronavirus spike S fusion protein core.
@en
Structural characterization of the SARS-coronavirus spike S fusion protein core.
@nl
P2093
P2860
P356
P1476
Structural characterization of the SARS-coronavirus spike S fusion protein core
@en
P2093
Brian Tripet
Megan W Howard
Randall K Holmes
Robert S Hodges
P2860
P304
20836-20849
P356
10.1074/JBC.M400759200
P407
P577
2004-03-02T00:00:00Z